Santen Pharmaceutical Co Stock Performance
| SNPHF Stock | USD 10.37 0.00 0.00% |
Santen Pharmaceutical has a performance score of 3 on a scale of 0 to 100. The entity has a beta of 0.16, which indicates not very significant fluctuations relative to the market. As returns on the market increase, Santen Pharmaceutical's returns are expected to increase less than the market. However, during the bear market, the loss of holding Santen Pharmaceutical is expected to be smaller as well. Santen Pharmaceutical right now has a risk of 1.52%. Please validate Santen Pharmaceutical jensen alpha, skewness, as well as the relationship between the Skewness and day typical price , to decide if Santen Pharmaceutical will be following its existing price patterns.
Risk-Adjusted Performance
3 of 100
Weak | Strong |
Insignificant
Compared to the overall equity markets, risk-adjusted returns on investments in Santen Pharmaceutical Co are ranked lower than 3 (%) of all global equities and portfolios over the last 90 days. Despite nearly stable technical indicators, Santen Pharmaceutical is not utilizing all of its potentials. The current stock price disturbance, may contribute to mid-run losses for the stockholders. ...more
| Begin Period Cash Flow | 62.9 B | |
| Total Cashflows From Investing Activities | -35.2 B |
Santen |
Santen Pharmaceutical Relative Risk vs. Return Landscape
If you would invest 1,002 in Santen Pharmaceutical Co on February 23, 2024 and sell it today you would earn a total of 35.00 from holding Santen Pharmaceutical Co or generate 3.49% return on investment over 90 days. Santen Pharmaceutical Co is currently producing 0.0661% returns and takes up 1.5199% volatility of returns over 90 trading days. Put another way, 13% of traded pink sheets are less volatile than Santen, and 99% of all traded equity instruments are likely to generate higher returns over the next 90 trading days. Expected Return |
| Risk |
Santen Pharmaceutical Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Santen Pharmaceutical's investment risk. Standard deviation is the most common way to measure market volatility of pink sheets, such as Santen Pharmaceutical Co, and traders can use it to determine the average amount a Santen Pharmaceutical's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0435
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | SNPHF | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 1.52 actual daily | 13 87% of assets are more volatile |
Expected Return
| 0.07 actual daily | 1 99% of assets have higher returns |
Risk-Adjusted Return
| 0.04 actual daily | 3 97% of assets perform better |
Based on monthly moving average Santen Pharmaceutical is performing at about 3% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Santen Pharmaceutical by adding it to a well-diversified portfolio.
Santen Pharmaceutical Fundamentals Growth
Santen Pink Sheet prices reflect investors' perceptions of the future prospects and financial health of Santen Pharmaceutical, and Santen Pharmaceutical fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Santen Pink Sheet performance.
| Return On Equity | -0.0264 | |||
| Return On Asset | -0.001 | |||
| Profit Margin | (0.03) % | |||
| Operating Margin | (0) % | |||
| Current Valuation | 2.6 B | |||
| Shares Outstanding | 388.22 M | |||
| Price To Earning | 14.54 X | |||
| Price To Book | 1.39 X | |||
| Price To Sales | 0.01 X | |||
| Revenue | 266.26 B | |||
| EBITDA | 53.91 B | |||
| Cash And Equivalents | 69.53 B | |||
| Cash Per Share | 176.84 X | |||
| Total Debt | 32.93 B | |||
| Debt To Equity | 0.1 % | |||
| Book Value Per Share | 780.63 X | |||
| Cash Flow From Operations | 46.04 B | |||
| Earnings Per Share | 0.50 X | |||
| Total Asset | 459.98 B | |||
| Retained Earnings | 230.22 B | |||
| Current Asset | 156.63 B | |||
| Current Liabilities | 50.32 B | |||
About Santen Pharmaceutical Performance
To evaluate Santen Pharmaceutical Pink Sheet as a possible investment, you need to clearly understand its upside potential, downside risk, and overall future performance outlook. You may be satisfied when Santen Pharmaceutical generates a 15% return over the last few months, but what if the market is generating 25% over the same period? In this case, it makes sense to compare Santen Pink Sheet's performance with different market indexes, such as the Dow or NASDAQ Composite. These indexes can act as benchmarks that will help you to understand Santen Pharmaceutical market performance in a much more refined way. The Macroaxis performance score is an integer between 0 and 100 that represents Santen's market performance from a risk-adjusted return perspective. Generally speaking, the higher the score, the better is overall performance as compared to other investors. The score is normalized against the average investing universe (the best we can interpret from the data available). Within this methodology, scores of individual equity instruments will always be inferior to the scores of portfolios of equities as portfolios typically diversify a lot of unsystematic risks away. The formula to derive the Macroaxis score bases on multiple unequally-weighted factors. For more information, refer to our portfolio performance evaluation section.
Please also refer to our technical analysis and fundamental analysis pages.Santen Pharmaceutical Co., Ltd. researches and develops, manufactures, and markets pharmaceuticals and medical devices in Japan and internationally. Santen Pharmaceutical Co., Ltd. was founded in 1890 and is headquartered in Osaka, Japan. Santen Pharmaceutical operates under Drug ManufacturersGeneral classification in the United States and is traded on OTC Exchange. It employs 4315 people.Things to note about Santen Pharmaceutical performance evaluation
Checking the ongoing alerts about Santen Pharmaceutical for important developments is a great way to find new opportunities for your next move. Pink Sheet alerts and notifications screener for Santen Pharmaceutical help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.Evaluating Santen Pharmaceutical's performance can involve analyzing a variety of financial metrics and factors. Some of the key considerations to evaluate Santen Pharmaceutical's pink sheet performance include:- Analyzing Santen Pharmaceutical's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Santen Pharmaceutical's stock is overvalued or undervalued compared to its peers.
- Examining Santen Pharmaceutical's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Santen Pharmaceutical's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Santen Pharmaceutical's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Santen Pharmaceutical's pink sheet. These opinions can provide insight into Santen Pharmaceutical's potential for growth and whether the stock is currently undervalued or overvalued.
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Santen Pharmaceutical Co. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in rate. Note that the Santen Pharmaceutical information on this page should be used as a complementary analysis to other Santen Pharmaceutical's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the ETFs module to find actively traded Exchange Traded Funds (ETF) from around the world.
Complementary Tools for Santen Pink Sheet analysis
When running Santen Pharmaceutical's price analysis, check to measure Santen Pharmaceutical's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Santen Pharmaceutical is operating at the current time. Most of Santen Pharmaceutical's value examination focuses on studying past and present price action to predict the probability of Santen Pharmaceutical's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Santen Pharmaceutical's price. Additionally, you may evaluate how the addition of Santen Pharmaceutical to your portfolios can decrease your overall portfolio volatility.
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
| CEOs Directory Screen CEOs from public companies around the world | |
| Transaction History View history of all your transactions and understand their impact on performance | |
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Bonds Directory Find actively traded corporate debentures issued by US companies | |
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
| ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
| Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
| Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios |